When HER2 status cannot be determined by standard work up

AI technology for interpretation of HER2 Low and practical application in the real-world settingПодробнее

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysisПодробнее

Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Ca...Подробнее

Helping to Address Unmet Needs in Metastatic HR+/HER2- Breast CancerПодробнее

Key challenge associated with the management of HR+/HER2- breast cancerПодробнее

What is HER2 low in breast cancer?Подробнее

New Perspectives on the Full Spectrum of HER2 Expression in Breast CancerПодробнее

HER2 Testing for the Pathologist: Is Your Clinic Up to Date With the Latest Developments?Подробнее

Remaining questions surrounding HER2-low breast cancer – how low can you go?Подробнее

Recent Updates in HR-Positive/HER2-Negative Early Breast Cancer: A Deep Dive Into Understanding t...Подробнее

Triple negative or Her2+? Check this out!Подробнее

Remaining questions regarding HER2-low breast cancerПодробнее

HER2CLIMB: outcomes by hormone receptor statusПодробнее

The exciting new field of HER2-low breast cancerПодробнее

Biological behaviour of HER2-low BC is dependent on HR expressionПодробнее

Current standards for HER2+ early stage breast cancerПодробнее

Oncology Today with Dr Neil Love: Optimizing the Identification of HER2-Low Breast CancerПодробнее

Dr. Sramila Aithal Describes the HERceptin Adjuvant (HERA) Trial for HER2-Positive Breast CancerПодробнее

Remaining questions on the management of HER2-low breast cancerПодробнее